Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PHASE 2, PROSPECTIVE, MULTI-CENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CEFEPIME-ZIDEBACTAM (FEP-ZID) WCK5222 FOR THE TREATMENT OF ADULT SUBJECTS WITH SERIOUS INFECTIONS CAUSED BY CARBAPENEM-RESISTANT GRAMNEGATIVE BACTERIA INCLUDING THOSE WITH UNDERLYING KIDNEY DYSFUNCTION PRECLUDING THE USE OF COLISTIN/POLYMYXIN B

Next Previous
X
Search
Trial Profile

A PHASE 2, PROSPECTIVE, MULTI-CENTER STUDY TO DETERMINE THE EFFICACY AND SAFETY OF CEFEPIME-ZIDEBACTAM (FEP-ZID) WCK5222 FOR THE TREATMENT OF ADULT SUBJECTS WITH SERIOUS INFECTIONS CAUSED BY CARBAPENEM-RESISTANT GRAMNEGATIVE BACTERIA INCLUDING THOSE WITH UNDERLYING KIDNEY DYSFUNCTION PRECLUDING THE USE OF COLISTIN/POLYMYXIN B

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cefepime/zidebactam (Primary)
  • Indications Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Urinary tract infections; Ventilator associated pneumonia
  • Focus Therapeutic Use

    • Most Recent Events

    • 04 Feb 2025 New trial record
    • 13 Jan 2025 Results presented in the Wockhardt Media Release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top